The Role of Complement in Myocardial Infarction Reperfusion Injury: An Underappreciated Therapeutic Target
- PMID: 33425913
- PMCID: PMC7793727
- DOI: 10.3389/fcell.2020.606407
The Role of Complement in Myocardial Infarction Reperfusion Injury: An Underappreciated Therapeutic Target
Abstract
This article reviews the pathogenetic role of the complement system in myocardial infarction reperfusion injury. The complement activation pathways involved in myocardial tissue injury are identified, as are the complement-derived effector molecules. The results of past anti-complement therapies are reviewed; as the more recent therapeutic concept of complement depletion with humanized CVF described.
Keywords: cobra venom factor; complement; complement depletion; humanized cobra venom factor; myocardial infarction; reperfusion injury.
Copyright © 2020 Vogel.
Conflict of interest statement
The author has a financial interest in iC3 LLC of Sunnyvale, CA, a company that develops therapeutics for complement depletion.
Figures
References
-
- Armstrong P. W., Mahaffey K. W., Chang W.-C., Weaver W. D., Hochmann J. S., Theroux P., et al. (2006). Concerning the mechanism of pexelizumab’s benefit in acute myocardial infarction. Amer. Heart J. 151 787–790. - PubMed
-
- Ferreira R. (2010). The reduction of infarct size – forty years of research. Rev. Port. Cardiol. 29 1037–1053. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
